近日,Omeros公司宣布,该公司的主打在研药物OMS 721获得FDA授予的突破性疗法认定,治疗免疫球蛋白A肾病。OMS721是Omeros公司开发的靶向甘露聚糖结合凝集素相关丝氨酸蛋白酶-2(MASP-2)的单克隆抗体。MASP-2是补体系统中凝集素信号通路的效应酶。OMS 721是公司开发的完全人源化MASP-2单克隆抗体。MASP-2是补体系统中凝集素信号通路的效应酶,凝集素通路被认为与很多组织损伤和病理学相关。通过抑制MASP-2的功能,OMS 721可以阻断一条激活补体系统的重要通路。 Recently, Omeros announced that the company’s flagship drug under study OMS 721 received the FDA’s grant of breakthrough therapy to treat immunoglobulin A nephropathy. OMS721 is a monoclonal antibody developed by Omeros that targets mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is an effector enzyme of the lectin signaling pathway in the complement system. OMS 721 is a fully humanized MASP-2 monoclonal antibody developed by the company. MASP-2 is an effector of the lectin signaling pathway in the complement system, and the lectin pathway is thought to be involved in many tissue damage and pathologies. By inhibiting the function of MASP-2, OMS 721 blocks an important pathway that activates the complement system.